QIAGEN expands presence in Thailand to serve life sciences

Food and Healthcare Press Releases Friday June 16, 2017 10:46
Bangkok--16 Jun--ABM
Opens Bangkok office and launches collaborations for malaria and cancer research

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced its expansion in Thailand and opened an office in Bangkok to enhance relationships with life science researchers and healthcare providers in the growing market. QIAGEN also announced two new collaborations in Thailand: a molecular techniques center established with the faculty for tropical medicine at Mahidol University and a collaboration with Ramathibodi Hospital to study genomic insights from next-generation sequencing (NGS).

"We are pleased to expand our commitment to the people of Thailand, where we have built relationships with medical institutions and the government for more than 16 years. As we open our new Bangkok office, we are also introducing new collaborations with two of the country's leading medical institutions," said Mr. William Lin, Director of Commercial Operations for QIAGEN Thailand. "We look forward to providing Thai scientists and healthcare providers with innovative Sample to Insight solutions for molecular testing, including our NGS solutions, as we seek to make improvements in life possible."

The collaboration with Mahidol University has established the QIAGEN–TropMed Center for Molecular Techniques in conjunction with the Faculty of Tropical Medicine to support research using molecular biology techniques.

"We are happy to join with QIAGEN in creating the TropMed Center for Molecular Techniques to bring the benefits of genomic insights to research on malaria and other diseases. Our partnership will demonstrate the potential of academic-industry collaboration, as well as educate the younger generation in techniques of molecular biology," said Dr. Wang Nguitragool, Assistant Professor, Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine of Mahidol University.

QIAGEN has joined with the Medical Genomic Center at Ramathibodi Hospital in Bangkok to help guide personalized healthcare treatment decisions using QIAGEN NGS solutions.

"QIAGEN NGS solutions, highly sensitive sequencing analyzes liquid biopsies or tissue samples to identify genetic mutations and enable doctors to select the best possible treatment. We expect this collaboration to have significant benefits for cancer patients," said Dr. Thanyanan Reungwetwattana, Assistant Professor, Division of Medical Oncology, Department of Medicine, Faculty of Medicine of Ramathibodi Hospital.

The expansion in Thailand supports QIAGEN's strategy of investing in emerging markets, where the use of advanced molecular technologies for medical care and research is growing rapidly. "The German-Thai Chamber of Commerce is proud to see another established German brand set root in Thailand. I am very happy to see that QIAGEN is expanding to Thailand because they bring their expertise to the local science community and contribute to the improvement of the life of the Thai people," said Dr. Roland Wein, Executive Director, German-Thai Chamber of Commerce. In 2016, QIAGEN sales in its top seven emerging markets grew 19% and contributed 16% of total net sales of $1.34 billion.


Latest Press Release

Swift Announces the Highest Throughput Single-Cell Methyl-Seq Library Preparation Method

Study published in Science magazine demonstrates how epigenetic markers can identify cell subtypes and regulatory elements that drive cellular diversity Swift Biosciences, a leading provider of innovative library prep solutions for next-generation...

Making it Easier to Understand Nutrition Labels

The Nutrition Facts label can provide you with lots of useful information—as long as you know how to read it correctly. Reading nutrition labels can be a challenge, because it always seems confusing and complicated. Oftentimes, you are discouraged...

Merck and Baylor College of Medicine Advance Vaccine Development and Manufacturing for Neglected Diseases

- Collaboration furthers both parties' commitment to advance research and development for neglected diseases - Agreement focuses on optimizing vaccine process development and formulation and exchanging know-how Merck , a leading science and technology...

NICE Recommends Erbitux(R) in Combination with Platinum-Based Chemotherapy for the Treatment of Recurrent and/or Metastatic Head and Neck Cancer in the Oral Cavity

- Decision secures access to Erbitux(R) for new patients in England with oral cavity tumors - All patients currently receiving Erbitux(R) will have continued access Merck, a leading science and technology company, announced today that the National...

European Patent Office to Grant Merck#s Patent Application for CRISPR Technology

- Patent application covers integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR - Related patent application recently awarded in Australia; similar patents pending in other countries, favourable outcomes...

Related Topics